Follow Astrana Health to never miss an important update.
The benchmark Treasury yield, which sets the tone for interest rates across the economy, rose above 5.1 percent on Wednesday. This was the largest one-day increase in over a year.
For a company like Astrana, higher yields can be a double-edged sword. While they often signal a strong economy, they also make it more expensive for companies to borrow money for expansions or acquisitions. Additionally, when yields on safe government bonds rise, investors often sell riskier stocks, which contributed to the market's drop today.
Source: WSJ
Pomerantz LLP and Lowey Dannenberg are looking into potential claims on behalf of shareholders regarding possible violations of federal securities laws. These types of investigations are common after a stock price drop or when questions arise about a company's financial disclosures. While they often do not lead to significant legal trouble, they can create a distraction for management and a cloud of uncertainty for the stock until the matters are resolved.
Source: GlobeNewsWire
Oppenheimer set its price target for Astrana at $53 per share. This is very close to the average target of $52 across all Wall Street firms that follow the company. Since the stock is currently trading around $34, analysts generally believe the business is worth significantly more than its current market price, though a price target is just an estimate and not a guarantee of where the stock will go.
Source: Oppenheimer
After a long string of misses, management has cleared the bar for two straight quarters. They are finally getting a handle on predicting their own growth as they integrate large acquisitions.
| Expectation | |
|---|---|
| EPS | $0.44 |
| Revenue | $1.02B |
Follow Astrana Health to get the latest and most important updates.
Follow ASTH